Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Lymphomatoid Granulomatosis in a Patient with Chronic Lymphocytic Leukemia and Rapidly Progressing Peribronchovascular Pulmonary Infiltrates.

Rezvani S, Tominna M, Al-Katib S, Smith MD, Cousineau C, Al-Katib A.

Case Rep Pulmonol. 2019 Jan 21;2019:9870494. doi: 10.1155/2019/9870494. eCollection 2019.

2.

Unintended target effect of anti-BCL-2 DNAi.

Ebrahim AS, Kandouz M, Emara N, Sugalski AB, Lipovich L, Al-Katib AM.

Cancer Manag Res. 2017 Sep 22;9:427-432. doi: 10.2147/CMAR.S139105. eCollection 2017.

3.

Composite Lymphoma: Opposite Ends of Spectrum Meet.

Khan U, Hadid T, Ibrar W, Sano D, Al-Katib A.

J Clin Med Res. 2017 Mar;9(3):213-215. doi: 10.14740/jocmr2929w. Epub 2017 Jan 25.

4.

Primary Cardiac Lymphoma: Lessons Learned from a Long Survivor.

Singh B, Ip R, Ibrahim Al-Rajjal A, Kafri Z, Al-Katib A, Hadid T.

Case Rep Cardiol. 2016;2016:7164829. doi: 10.1155/2016/7164829. Epub 2016 Dec 7.

5.

Spatio-temporal regulation of EGFR signaling by the Eps15 homology domain-containing protein 3 (EHD3).

Amessou M, Ebrahim AS, Dilly A, Joseph M, Tabolina M, Chukkapalli S, Meroueh L, Syed JT, Liddane A, Lang SL, Al-Katib A, Kandouz M.

Oncotarget. 2016 Nov 29;7(48):79203-79216. doi: 10.18632/oncotarget.13008.

6.

Thrombotic thrombocytopenic purpura presenting as acute coronary syndrome.

Mouabbi JA, Zein R, Kafri Z, Al-Katib A, Hadid T.

Clin Case Rep. 2016 Jun 21;4(8):736-9. doi: 10.1002/ccr3.606. eCollection 2016 Aug.

7.

PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma.

Ebrahim AS, Kandouz M, Liddane A, Sabbagh H, Hou Y, Li C, Al-Katib A.

Oncotarget. 2016 Jul 5;7(27):42374-42384. doi: 10.18632/oncotarget.9872.

8.

Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting.

Hadid T, Raufi A, Kafri Z, Mandziara M, Kalabat J, Szpunar S, Kolizeras K, Steigelman M, Al-Katib A.

Nucl Med Biol. 2016 Apr;43(4):227-31. doi: 10.1016/j.nucmedbio.2015.12.004. Epub 2016 Jan 6.

PMID:
27067042
9.

Hematologic malignancies: newer strategies to counter the BCL-2 protein.

Ebrahim AS, Sabbagh H, Liddane A, Raufi A, Kandouz M, Al-Katib A.

J Cancer Res Clin Oncol. 2016 Sep;142(9):2013-22. doi: 10.1007/s00432-016-2144-1. Epub 2016 Apr 4. Review.

PMID:
27043233
10.

Genomic uracil homeostasis during normal B cell maturation and loss of this balance during B cell cancer development.

Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS.

Mol Cell Biol. 2014 Nov;34(21):4019-32. doi: 10.1128/MCB.00589-14. Epub 2014 Aug 25.

11.

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A.

Cancer Chemother Pharmacol. 2014 Jul;74(1):151-66. doi: 10.1007/s00280-014-2476-y. Epub 2014 May 16.

12.

Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies.

Al-Katib AM, Aboukameel A, Ebrahim A, Beck FW, Tekyi-Mensah SE, Raufi A, Ahmed Y, Mandziara M, Kafri Z.

Exp Hematol Oncol. 2014 Dec 19;3:31. doi: 10.1186/2162-3619-3-31. eCollection 2014.

13.

Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.

Raufi A, Ebrahim AS, Al-Katib A.

Cancer Manag Res. 2013 Aug 27;5:225-33. doi: 10.2147/CMAR.S45957. eCollection 2013. Review.

14.

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.

Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, Shacham S, Mohammad RM.

Haematologica. 2013 Jul;98(7):1098-106. doi: 10.3324/haematol.2012.074781. Epub 2013 Feb 12.

15.

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM.

J Hematol Oncol. 2012 Sep 18;5:57. doi: 10.1186/1756-8722-5-57.

16.

Syncytial giant cell hepatitis associated with chronic lymphocytic leukemia: a case report.

Gupta E, Yacoub M, Higgins M, Al-Katib AM.

BMC Blood Disord. 2012 Jul 19;12:8. doi: 10.1186/1471-2326-12-8.

17.

Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.

Obeid KM, Aguilar J, Szpunar S, Sharma M, del Busto R, Al-Katib A, Johnson LB.

Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):66-9. doi: 10.1016/j.clml.2011.07.006. Epub 2011 Oct 14.

PMID:
22000698
18.

I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.

Al-Katib A, Arnold AA, Aboukameel A, Sosin A, Smith P, Mohamed AN, Beck FW, Mohammad RM.

Mol Cancer. 2010 Sep 1;9:228. doi: 10.1186/1476-4598-9-228.

19.

New targets for the treatment of follicular lymphoma.

Tageja N, Padheye S, Dandawate P, Al-Katib A, Mohammad RM.

J Hematol Oncol. 2009 Dec 23;2:50. doi: 10.1186/1756-8722-2-50. Review.

20.

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM.

Mol Cancer. 2009 Dec 3;8:115. doi: 10.1186/1476-4598-8-115.

21.

Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.

Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C.

Clin Cancer Res. 2009 Jun 15;15(12):4038-45. doi: 10.1158/1078-0432.CCR-08-2808. Epub 2009 Jun 9.

22.

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.

Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, Mohammad RM.

J Hematol Oncol. 2009 Feb 16;2:8. doi: 10.1186/1756-8722-2-8.

23.

Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.

Sun Y, Wu J, Aboukameel A, Banerjee S, Arnold AA, Chen J, Nikolovska-Coleska Z, Lin Y, Ling X, Yang D, Wang S, Al-Katib A, Mohammad RM.

Cancer Biol Ther. 2008 Sep;7(9):1418-26. Epub 2008 Sep 4.

24.

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.

Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, Mohammad RM.

Mol Cancer. 2008 Feb 14;7:20. doi: 10.1186/1476-4598-7-20.

25.

Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.

Mohamed AN, Bentley G, Bonnett ML, Zonder J, Al-Katib A.

Am J Hematol. 2007 Dec;82(12):1080-7.

26.

Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.

Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A.

Clin Cancer Res. 2007 Apr 1;13(7):2226-35.

27.

Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma.

Jenkins BD, Snower D, Mohamed A, Al-Katib A.

Am J Hematol. 2005 Jun;79(2):128-31.

28.

Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.

Hamdy N, Goustin AS, Desaulniers JP, Li M, Chow CS, Al-Katib A.

J Immunol Methods. 2005 Feb;297(1-2):109-24. Epub 2005 Jan 11.

PMID:
15777935
29.

Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.

Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A.

Mol Cancer Ther. 2005 Jan;4(1):13-21.

30.

Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.

Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A.

Leuk Lymphoma. 2004 Oct;45(10):2079-84.

PMID:
15370253
31.

Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.

Beck FW, Eilender DS, Dandashi MH, Siddiq F, Snell DC, Godmere MA, Al-Katib AM, Mohammad RM.

Int J Mol Med. 2004 Jul;14(1):113-9.

PMID:
15202025
32.

Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.

Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O.

Mol Cancer Ther. 2003 Dec;2(12):1361-8.

34.

XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.

Mensah-Osman E, Al-Katib A, Dandashi M, Mohammad R.

Int J Oncol. 2003 Dec;23(6):1637-44.

PMID:
14612935
35.

The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.

Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R.

Semin Oncol. 2003 Apr;30(2):313-7.

PMID:
12720160
36.

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA.

Semin Oncol. 2003 Apr;30(2):110-5. Review.

PMID:
12720118
39.
40.

Banded chromosomes versus fluorescence in situ hybridization in the diagnosis of mantle cell lymphoma: a lesson from three cases.

Mohamed AN, Ali W, Kopptich F, al Katib A.

Cancer Genet Cytogenet. 2002 Jul 15;136(2):108-12.

PMID:
12237233
41.

Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.

Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM.

Clin Cancer Res. 2002 Aug;8(8):2735-41.

42.

Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation.

Vaishampayan U, Karanes C, Du W, Varterasian M, al-Katib A.

Cancer Invest. 2002;20(3):303-10.

PMID:
12025224
43.
44.

Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.

Wall NR, Beck FW, Al-Katib AM, Mohammad RM.

J Drug Target. 2001;9(5):329-39.

PMID:
11770703
45.
46.

Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.

Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM.

Invest New Drugs. 2001;19(3):245-7.

PMID:
11561682
47.

Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant.

Mohamed AN, Palutke M, Eisenberg L, Al-Katib A.

Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51. Review.

PMID:
11343778
48.

Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.

Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM.

Anticancer Drugs. 2001 Jan;12(1):57-63.

PMID:
11272287
50.

Multiple myeloma in the liver.

Kaur J, Turner JR, Singh P, Al-Katib A.

Am J Hematol. 2000 Dec;65(4):290. No abstract available.

PMID:
11074556

Supplemental Content

Loading ...
Support Center